Array BioPharma Inc.
| NASDAQ: ARRY | Healthcare / Biotechnology / USA |
| 20.33 | +0.7850 | +4.02% | Vol 6.95M | 1Y Perf - |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 19.41 | ASK | 20.37 | ||
| Open | 19.69 | Previous Close | 19.55 | ||
| Pre-Market | - | After-Market | 20.33 | ||
| - - | - -% |
| Target Price | 26.75 | Analyst Rating | Strong Buy 1.49 | |
| Potential % | 31.58 | Finscreener Ranking | ★★★ 50.01 | |
| Insiders Trans % 3/6/12 mo. | -50/-50/-20 | Value Ranking | ★ 39.51 | |
| Insiders Value % 3/6/12 mo. | 42/42/54 | Growth Ranking | ★+ 42.85 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 40/40/49 | Income Ranking | — - | |
| Price Range Ratio 52W % | 50.63 | Earnings Rating | Strong Sell | |
| Market Cap | 3.07B | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.00 | Standard Deviation | 0.24 | |
| Beta | 1.80 |
Today's Price Range 19.0920.35 | 52W Range 13.8626.64 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | - | ||
| 3 Months | - | ||
| 6 Months | - | ||
| 1 Year | - | ||
| 3 Years | - | ||
| 5 Years | 29.78% | ||
| 10 Years | 201.16% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -155.20 | |||
ROE last 12 Months | -160.74 | |||
ROA (5Y Avg) | -5.56 | |||
ROA last 12 Months | -4.67 | |||
ROC (5Y Avg) | -37.76 | |||
ROC last 12 Months | -6.35 | |||
Return on invested Capital Q | 4.01 | |||
Return on invested Capital Y | 12.02 | |||
Assets Turnover | 0.90 | |||
Receivables Turnover | 3.50 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -45.70 | ||||
| 45.62 | ||||
| 2.37 | ||||
| 60.70 | ||||
| -7.90 | ||||
| -0.37 | ||||
| -4.14 | ||||
| 0.41 | ||||
| 3.82B | ||||
| Forward PE | 16.68 | |||
| PEG | -0.91 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 1.70 | ||||
| 0.67 | ||||
| 12.50 | ||||
| 0.00 | ||||
| Leverage Ratio | 22.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.80 | ||||
| -0.10 | ||||
| 5.30 | ||||
| -58.70 | ||||
| 1.10 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.24B | ||||
| 8.21 | ||||
| 15.84 | ||||
| 25.13 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | 0.17 | 0.41 | 141.18 |
| Q01 2023 | 0.01 | 0.23 | 2.20K |
| Q04 2022 | 0.08 | 0.09 | 12.50 |
| Q03 2022 | 0.10 | 0.16 | 60.00 |
| Q02 2022 | 0.02 | 0.06 | 200.00 |
| Q01 2022 | -0.09 | -0.05 | 44.44 |
| Q04 2021 | - | -0.07 | - |
| Q03 2021 | -0.05 | -0.08 | -60.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | 0.09 | -64.00 | Negative |
| 12/2023 QR | 0.17 | 6.25 | Positive |
| 12/2023 FY | 0.94 | 11.90 | Positive |
| 12/2024 FY | 1.33 | 10.83 | Positive |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | 0.09 |
| Estimates Count | 10 |
| EPS Growth Next 5 Years % | 50.30 |
| Volume Overview | |
|---|---|
| Volume | 6.95M |
| Shares Outstanding | 151.07K |
| Shares Float | 142.42M |
| Trades Count | 61.62K |
| Dollar Volume | 137.58M |
| Avg. Volume | 1.47M |
| Avg. Weekly Volume | 1.09M |
| Avg. Monthly Volume | 0 |
| Avg. Quarterly Volume | 3.30M |
Array BioPharma Inc. (NASDAQ: ARRY) stock closed at 11.3 per share at the end of the most recent trading day (a 3.59% change compared to the prior day closing price) with a volume of 4.04M shares and market capitalization of 3.07B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs people. Array BioPharma Inc. CEO is .
The one-year performance of Array BioPharma Inc. stock is %, while year-to-date (YTD) performance is 72.96%. ARRY stock has a five-year performance of 29.78%. Its 52-week range is between 13.86 and 26.64, which gives ARRY stock a 52-week price range ratio of 50.63%
Array BioPharma Inc. currently has a PE ratio of -45.70, a price-to-book (PB) ratio of 45.62, a price-to-sale (PS) ratio of 2.37, a price to cashflow ratio of 60.70, a PEG ratio of -0.91, a ROA of -4.67%, a ROC of -6.35% and a ROE of -160.74%. The company’s profit margin is 1.10%, its EBITDA margin is 5.30%, and its revenue ttm is $1.24 Billion , which makes it $8.21 revenue per share.
Of the last four earnings reports from Array BioPharma Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.09 for the next earnings report. Array BioPharma Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Array BioPharma Inc. is Strong Buy (1.49), with a target price of $26.75, which is +31.58% compared to the current price. The earnings rating for Array BioPharma Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Array BioPharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Array BioPharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 62.62, ATR14 : 1.02, CCI20 : 1.69, Chaikin Money Flow : 0.14, MACD : 0.00, Money Flow Index : 55.84, ROC : 10.78, RSI : 0.00, STOCH (14,3) : 35.59, STOCH RSI : 0.00, UO : 48.37, Williams %R : -64.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Array BioPharma Inc. in the last 12-months were: Patel Nipul (Sold 54 593 shares of value $1 262 190 )
Array BioPharma Inc.
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.
CEO:
Telephone: +1 303 381-6600
Address: 3200 Walnut Street, Boulder 80301, CO, USA
TipRanks News for ARRY
Mon, 14 Aug 2023 02:25 GMT Array Technologies (ARRY) Gets a Buy from Truist Financial
- TipRanks. All rights reserved.Wed, 09 Aug 2023 13:40 GMT Unusually active option classes on open August 9th
- TipRanks. All rights reserved.
